The role of PRMT1 in cellular regulation and disease: Insights into biochemical functions and emerging inhibitors for cancer therapy
- PMID: 39521191
- DOI: 10.1016/j.ejps.2024.106958
The role of PRMT1 in cellular regulation and disease: Insights into biochemical functions and emerging inhibitors for cancer therapy
Erratum in
-
Corrigendum to "The role of PRMT1 in cellular regulation and disease: Insights into biochemical functions and emerging inhibitors for cancer therapy" [European Journal of Pharmaceutical Sciences Volume 204, 1 January 2025, 106958].Eur J Pharm Sci. 2025 Mar 1;206:107009. doi: 10.1016/j.ejps.2025.107009. Epub 2025 Jan 17. Eur J Pharm Sci. 2025. PMID: 39827078 No abstract available.
Abstract
Protein Arginine Methyltransferase 1 (PRMT1), a primary protein arginine methyltransferase, plays a pivotal role in cellular regulation, influencing processes such as gene expression, signal transduction, and cell differentiation. Dysregulation of PRMT1 has been linked to the development of various cancers, establishing it as a key target for therapeutic intervention. This review synthesizes the biochemical characteristics, structural domains, and functional mechanisms of PRMT1, focusing on its involvement in tumorigenesis. Additionally, the development and efficacy of emerging PRMT1 inhibitors as potential cancer therapies are examined. By employing molecular modeling and insights from existing literature, this review posits that targeting PRMT1's methyltransferase activity could disrupt cancer progression, providing valuable insights for future drug development.
Keywords: Arginine methylation; Cancer therapy; Inhibitors; PRMT1; Tumorigenesis.
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest None.
Similar articles
-
Overview of PRMT1 modulators: Inhibitors and degraders.Eur J Med Chem. 2024 Dec 5;279:116887. doi: 10.1016/j.ejmech.2024.116887. Epub 2024 Sep 19. Eur J Med Chem. 2024. PMID: 39316844 Review.
-
Discovery of a first-in-class protein arginine methyltransferase 1 (PRMT1) degrader for nonenzymatic functions studies.Eur J Med Chem. 2025 Jul 5;291:117625. doi: 10.1016/j.ejmech.2025.117625. Epub 2025 Apr 14. Eur J Med Chem. 2025. PMID: 40245820
-
PRMT1 in human neoplasm: cancer biology and potential therapeutic target.Cell Commun Signal. 2024 Feb 8;22(1):102. doi: 10.1186/s12964-024-01506-z. Cell Commun Signal. 2024. PMID: 38326807 Free PMC article. Review.
-
Design and synthesis of novel PRMT1 inhibitors and investigation of their binding preferences using molecular modelling.Bioorg Med Chem Lett. 2017 Oct 15;27(20):4635-4642. doi: 10.1016/j.bmcl.2017.09.016. Epub 2017 Sep 8. Bioorg Med Chem Lett. 2017. PMID: 28927791
-
PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin.Cell Rep. 2020 Jan 28;30(4):1208-1222.e9. doi: 10.1016/j.celrep.2019.12.061. Cell Rep. 2020. PMID: 31995759
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical